双相障碍的分期:从理论框架到临床效用
本文综述双相障碍分期模型的证据,认为疾病沿可预测路径进展:高危/潜伏期、前驱期至首次临床阈值发作、多次复发后可能进展至晚期。分期效用取决于其与临床结局、治疗反应及神经生物学指标(生化、神经影像、认知改变)的关联。分期模型提示针对不同阶段采取预防、早期干预、复杂联合治疗或姑息治疗,以阻止神经进展。
要点
- 双相障碍分期模型假设疾病沿可预测路径进展,从高危期到晚期表现。
- 分期效用需与临床结局、治疗反应及神经生物学指标关联验证。
- 分期模型建议阶段特异性治疗,包括预防、早期干预、联合治疗和姑息治疗。
核心结论
- 双相障碍分期模型有理论框架支持,但需进一步验证其与临床结局、治疗反应和神经生物学指标的关联。
- 分期模型提示早期干预可能阻止或减缓神经进展和功能恶化。
研究设计与样本
- 本文为综述,探讨双相障碍分期模型的证据、验证尝试、研究方向及临床意义。
主要发现
- 双相障碍分期模型假设疾病沿可预测路径进展:高危/潜伏期、前驱期至首次临床阈值发作、多次复发后可能进展至晚期。
- 分期模型的效用和效度取决于其与临床结局、治疗反应及神经生物学指标(如生化、神经影像和认知改变)的关联。
- 分期模型提示存在主动疾病过程,若未纠正可导致神经进展、更恶性病程和功能恶化。
- 涉及的生物学因素包括遗传素质、躯体和心理创伤、表观遗传改变、神经发生和凋亡改变、线粒体功能障碍、炎症和氧化应激。
- 许多药物如锂盐对这些靶点有作用。
关键数值与推荐
- 分期模型建议阶段特异性治疗:对高危个体预防、对前驱期和新诊断个体早期干预、对快速复发者复杂联合治疗、对慢性晚期者姑息治疗。
临床怎么用
- 临床可根据分期模型对双相障碍患者进行阶段评估,并采取相应的阶段特异性治疗策略。
- 早期启动可能改变疾病的治疗有望预防或减缓双相障碍晚期的认知和结构改变。
局限性
- 文章未报告具体研究样本量、数值或验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Illness staging is widely utilized in several medical disciplines to help predict course or prognosis, and optimize treatment. Staging models in psychiatry in general, and bipolar disorder in particular, depend on the premise that psychopathology moves along a predictable path: an at-risk or latency stage, a prodrome progressing to a first clinical threshold episode, and one or more recurrences with the potential to revert or progress to late or end-stage manifestations. The utility and validity of a staging model for bipolar disorder depend on its linking to clinical outcome, treatment response and neurobiological measures. These include progressive biochemical, neuroimaging and cognitive changes, and potentially stage-specific differences in response to pharmacological and psychosocial treatments. Mechanistically, staging models imply the presence of an active disease process that, if not remediated, can lead to neuroprogression, a more malignant disease course and functional deterioration. Biological elements thought to be operative in bipolar disorder include a genetic diathesis, physical and psychic trauma, epigenetic changes, altered neurogenesis and apoptosis, mitochondrial dysfunction, inflammation, and oxidative stress. Many available agents, such as lithium, have effects on these targets. Staging models also suggest the utility of stage-specific treatment approaches that may not only target symptom reduction, but also impede illness neuroprogression. These treatment approaches range from prevention for at-risk individuals, to early intervention strategies for prodromal and newly diagnosed individuals, complex combination therapy for rapidly recurrent illness, and palliative-type approaches for those at chronic, late stages of illness. There is hope that prompt initiation of potentially disease modifying therapies may preclude or attenuate the cognitive and structural changes seen in the later stages of bipolar disorder. The aims of this paper are to: a) explore the current level of evidence supporting the descriptive staging of the syndromal pattern of bipolar disorder; b) describe preliminary attempts at validation; c) make recommendations for the direction of further studies; and d) provide a distillation of the potential clinical implications of staging in bipolar disorder within a broader transdiagnostic framework.
引用
- Berk M, Post R, Ratheesh A, et al. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry. 2017. PMID: 28941093. doi:10.1002/wps.20441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。